Manila Times Business
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
PET-CT imaging, Rather than CT Alone, Presented a Meaningful Reduction in Tumor Metabolic Activity After Treatment, Suggesting that PET May Help to Optimize Therapeutic Response Monitoring Following Treatment Delivered via Trans-Arterial Micro-Perfusion (TAMP) MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx” or "the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FD
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Ambros Therapeutics Appoints Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D., as SVP of Clinical Operations and Program Management
2h ago
Manganese X Energy to Present at the June 16 Energy & Precious Metals Virtual Investor Summit
2h ago
Energy & Precious Metals Virtual Investor Summit Agenda Announced for June 16th
2h ago
WatchMatic Highlights Market Trends Influencing Luxury Watch Investment Strategies
2h ago